TY - JOUR
T1 - Water Intoxication Following Moderate-Dose Intravenous Cyclophosphamide
AU - Bressler, Robert B.
AU - Huston, David P.
PY - 1985/3
Y1 - 1985/3
N2 - Moderate-dose (15 to 20 mg/kg) bolus intravenous (IV) cyclophosphamide is increasingly being employed for the treatment of autoimmune diseases. High-dose (30 to 50 mg/kg) IV cyclophosphamide, which is used in transplantation and oncology, may cause water intolerance and water intoxication. Described herein is the first patient, to our knowledge, to develop water intoxication following administration of moderate-dose IV cyclophosphamide. A water challenge test demonstrated the absence of an underlying syndrome of inappropriate antidiuretic hormone secretion. Water intolerance was demonstrated in five additional patients receiving moderate-dose IV cyclophosphamide and hydration with hypotonic fluids. Thus, contrary to previous reports, water intoxication can occur following administration of moderate-dose IV cyclophosphamide. Patients with renal insufficiency who are receiving hypotonic fluids following moderate-dose IV cyclophosphamide administration may be at greatest risk for development of symptomatic water intoxication.
AB - Moderate-dose (15 to 20 mg/kg) bolus intravenous (IV) cyclophosphamide is increasingly being employed for the treatment of autoimmune diseases. High-dose (30 to 50 mg/kg) IV cyclophosphamide, which is used in transplantation and oncology, may cause water intolerance and water intoxication. Described herein is the first patient, to our knowledge, to develop water intoxication following administration of moderate-dose IV cyclophosphamide. A water challenge test demonstrated the absence of an underlying syndrome of inappropriate antidiuretic hormone secretion. Water intolerance was demonstrated in five additional patients receiving moderate-dose IV cyclophosphamide and hydration with hypotonic fluids. Thus, contrary to previous reports, water intoxication can occur following administration of moderate-dose IV cyclophosphamide. Patients with renal insufficiency who are receiving hypotonic fluids following moderate-dose IV cyclophosphamide administration may be at greatest risk for development of symptomatic water intoxication.
UR - http://www.scopus.com/inward/record.url?scp=0021940374&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021940374&partnerID=8YFLogxK
U2 - 10.1001/archinte.1985.00360030196034
DO - 10.1001/archinte.1985.00360030196034
M3 - Article
C2 - 3977522
AN - SCOPUS:0021940374
SN - 0003-9926
VL - 145
SP - 548
EP - 549
JO - Archives of Internal Medicine
JF - Archives of Internal Medicine
IS - 3
ER -